🇺🇸

US SEC Filing Intelligence

· daily

Contract Option Exercises — March 29, 2026

Option exercises totaling $1.33B signal strong long-term U.S. government commitments through 2029, dominated by HHS ($699M across two contracts) in software publishing and biomed R&D, yielding 4 bullish signals for Leidos Holdings, Carahsoft, IDEMIA, and NISA. Neutral stance on nonprofit Family Endeavors due to T&M pricing and short horizon despite $3.3B options upside. Investors should prioritize public Leidos for predictable revenue, monitor $0 outlays on IDEMIA's $204M, and track HHS expansion risks/opportunities.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — March 29, 2026

Carahsoft Technology Corp secured a $465M obligated delivery order from CMS (HHS) for income verification software, with $337M already outlayed and potential upside to $2.1B via options through 2028. This represents a major bullish signal for federal IT/software publishers amid healthcare admin digitization. Investors should monitor option exercises and outlays for revenue acceleration, tempered by firm-fixed-price margin risks.

1 total filings
· daily

All HHS Contracts — March 29, 2026

HHS data reveals $698.6M in major contracts to Carahsoft ($465M obligation, $2.07B potential) for CMS income verification software and Leidos ($233.6M fully obligated) for NIH COVID-19 R&D, both bullish with $493.5M (71%) already outlayed for multi-year revenue through 2029. These awards underscore sustained HHS demand for digital verification tools and biomed R&D amid full/open competition. Investors gain clear long-term visibility, prioritizing Carahsoft's massive option upside.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 29, 2026

Four mega contracts totaling $1.25B in obligations highlight sustained federal spending in HHS (56% of value) for software verification and biomedical R&D, plus facilities support and passport services, with 3 bullish signals for corporate recipients. Massive optionality exceeds $5.6B combined (Carahsoft $2.1B, Family Endeavors $3.3B), offering multi-year upside through 2029, though $0 outlays on IDEMIA's 2017 award flags execution delays. Investors should prioritize Leidos and Carahsoft for stable health/tech revenues amid long-duration commitments.

4 total filings
· daily

High-Value Federal Grants ($5M+) — March 29, 2026

Five high-value federal contracts total $1.33B obligated (potential $8.8B with options), dominated by HHS awards (52% of value) signaling robust health/services demand. Four bullish signals highlight long-term revenue for Leidos Holdings, Carahsoft, IDEMIA, and NISA, with 47% average outlay progress and extensions to 2029. Neutral Family Endeavors stands out as nonprofit with 10x option upside amid facilities support needs.

5 total filings
· daily

General Federal Contracts — March 29, 2026

Federal contracts totaling $1.33B obligated, with 4/5 bullish signals dominated by HHS ($698.6M across software verification and COVID R&D), signaling robust health sector commitments through 2028-2029. Long-term performance periods (avg. ~4-10 years remaining) and partial outlays ($865M total) indicate steady revenue visibility for winners like Carahsoft and Leidos. Neutral signal on nonprofit Family Endeavors highlights facilities support scale-up potential amid options exceeding $3.3B.

5 total filings
· daily

Significant Contract Modifications ($10M+) — March 28, 2026

A single significant $108M contract modification awarded to CGI Federal Inc. (Timken subsidiary) for EPA IT enterprise development signals strong federal demand in IT services, with potential expansion to $523M via options through 2030. This bullish development underscores GSA's reliance on cost-plus structures for environmental agency tech support. Investors should monitor option exercises amid execution risks from subawards and performance fees.

1 total filings
· daily

Contract Deobligations Alert — March 28, 2026

CGI Federal Inc., listed as a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT support, with potential expansion to $523M through options extending to 2030. No outlays yet signal early-stage execution, presenting bullish upside if options are exercised amid zero deobligations in this period. Investors should monitor performance evaluations and subaward costs for margin risks in govcon IT.

1 total filings
· daily

Contract Option Exercises — March 28, 2026

CGI Federal Inc., a Timken Company subsidiary, secured a $108M GSA delivery order for EPA IT enterprise development, with potential expansion to $523M via options through 2030. This bullish signal provides multi-year revenue visibility in government IT services, though realization hinges on performance-based options and award fees. No outlays yet signal early-stage execution, warranting monitoring for margin impacts from $15M subawards.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 28, 2026

CGI Federal Inc. secured a $108M obligated GSA delivery order for EPA IT enterprise development, with potential expansion to $522M through options by 2030, signaling strong federal demand in IT services. No funds outlayed yet, but long performance window to 2030 offers upside if options exercised. Investors should monitor performance evaluations amid subaward commitments and cost-plus structure risks.

1 total filings
· daily

Biotech Small-Cap Approvals — March 27, 2026

Two small-cap biotech ANDA approvals on March 24, 2026, for Ascent Pharms (Guanfacine Hydrochloride) and Zhejiang Jingxin (Ticagrelor) signal neutral generic market entries with no special designations or specified indications. Lacking premium positioning or expedited review, these offer limited differentiation amid standard generic competition. Investors should note steady commoditization in biotech small-caps but no material portfolio catalysts.

2 total filings
· daily

New Drug Approvals (Original) — March 27, 2026

FDA approved two generic ANDA products on March 24, 2026: Guanfacine Hydrochloride (Ascent Pharms Inc) and Ticagrelor (Zhejiang Jingxin), both under standard review with no special designations or specified indications. Neutral investment signals prevail due to generic nature and lack of differentiation or market details. Pattern indicates routine generic pipeline progress without material sector disruption or premium opportunities.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 27, 2026

Three bullish federal contracts totaling $472M signal sustained U.S. government demand for construction in infrastructure resilience, embassy facilities, and disaster recovery across DOI, DOS, and DHS. Full base+options obligations provide revenue visibility to 2027 for Tutor Perini ($117M), Caddell ($168M), and BWI TPC JV ($187M near-complete), though firm-fixed-price terms and low aggregate outlays (~40%) flag execution risks. Cross-pattern: Full/open awards to non-small contractors highlight competitive strength in NAICS 236220/237990, with phased/hurricane work priming follow-ons.

3 total filings
· daily

DHS Homeland Security Contracts — March 27, 2026

Tutor Perini Corporation secured a $117M fully obligated firm fixed price contract from the U.S. Coast Guard for San Juan hurricane rebuild, providing committed revenue visibility through 2027-12-30. This single large award signals bullish momentum for the company in DHS infrastructure but flags execution risks from cost overruns and zero outlays to date. Investors should monitor progress for portfolio exposure to construction firms with federal disaster recovery expertise.

1 total filings
· daily

VA Healthcare & Services Contracts — March 27, 2026

ThunderCat Technology, LLC, a SDVOSB, won a $221.9M obligated VA delivery order (base + options: $1.56B) for Intersystems IT software support, with $74M already outlayed, marking a major bullish signal for VA healthcare IT spending. Potential extension to 2030 offers substantial revenue upside if options exercised, though firm-fixed pricing introduces cost overrun risks. Single-contract concentration highlights targeted opportunities in SDVOSB-aligned VA procurements amid full-and-open competition.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 27, 2026

HHS's BARDA issued an $88.9M cost-plus-fixed-fee contract to nonprofit ATCC for biological sample storage/distribution in MCM evaluation, with performance through 2028-09-26 and only $4.8M outlayed to date, signaling sustained federal health R&D funding but neutral equity implications due to recipient's tax-exempt status. The full obligation including all options offers revenue visibility amid health preparedness priorities. Investors face execution risks from low early spend and long duration, with limited direct plays but potential sector spillover.

1 total filings